About Admin

This author has not yet filled in any details.
So far Admin has created 78 blog entries.

Kallelse till extra bolagsstämma i Biovica International AB

Kallelse till extra bolagsstämma i Biovica International AB Styrelsen i Biovica International AB, org.nr 556774-6150, kallar härmed till extra bolagsstämma. Datum: 2 mars 2017 Tid: 16:00 Plats: Dag Hammarskjölds väg 54B i Uppsala Anmälan/rätt att delta på stämman Aktieägare som vill delta i bolagsstämman ska vara införd i den av Euroclear Sweden AB förda [...]

2017-02-22T13:34:57+00:00 February 7th, 2017 17:09|Press Release|

Biovica interviewed about the upcoming IPO

Anders Rylander, CEO of Biovica and Mattias Bergqvist, VP Marketing & Clinical Development discuss the challenges in cancer diagnostics, go-to-market strategies, clinical results and IPO preparations in the latest edition of Vatorpodden. The interview is available in Swedish (only)

2017-02-03T17:04:13+00:00 February 3rd, 2017 14:56|News|

Biovica discuss the latest clinical results in Vatorpodden

Listen to Anders Rylander, CEO of Biovica and Mattias Bergqvist VP Sales & Marketing being interviewed in the latest edition of Vatorpodden. Anders and Mattias discuss the latest clinical results presented at the 2016 San Antonio Breast Cancer Symposium. The interview is available in Swedish (only)

2017-02-03T14:56:27+00:00 January 2nd, 2017 15:00|News|

Kallelse till extra bolagsstämma

Kallelse till extra bolagsstämma i Biovica International AB Styrelsen i Biovica International AB, org.nr 556774-6150, kallar härmed till extra bolagsstämma. Datum:          24 januari 2017 Tid:                16:00 Plats:             Nybrokajen 7, 6 tr, Stockholm Anmälan/rätt att delta på stämman Aktieägare som vill delta i bolagsstämman skall vara införd i den av Euroclear Sweden AB förda aktieboken [...]

2017-01-04T13:53:20+00:00 December 21st, 2016 13:00|Press Release|

Unique results demonstrate DiviTum™ capabilities

Unique results show DiviTum™ is able to evaluate the anti-tumor activity of blockbuster cancer drug [Uppsala, Sweden, December 12, 2016] - New clinical study results presented at the San Antonio Breast Cancer Symposium, the world’s leading breast cancer conference, 6-10 December 2016, demonstrate that Biovica’s DiviTum™ biomarker assay can evaluate the efficacy of [...]

2017-01-17T15:19:03+00:00 December 12th, 2016 08:30|Press Release|

Biovica participates at SABCS, december 6-10, San Antonio

Biovica will attend the San Antonio Breast Cancer Symposium, an event that brings together oncology professionals from around the world. SABCS is the world’s leading breast cancer congress attracting more than 7,500 attendees from 90 countries. Read more at sabcs.org “At SABCS we will present new clinical study results in collaboration [...]

2017-01-04T13:53:59+00:00 November 25th, 2016 13:30|News|

Biovica and Eisai inc. enter into lab services agreement

[Uppsala, Sweden, October 26, 2016]— Biovica and Eisai Inc. have entered into a lab services agreement to analyze DiviTum™, an assay measuring serum thymidine kinase, for improved drug evaluation in animal cancer models. In a preclinical setting at Eisai’s Andover innovative Medicine’s (AiM) Institute, Biovica’s non-invasive DiviTum™ technology will be used to test for evidence [...]

2017-01-03T10:41:49+00:00 October 26th, 2016 08:30|Press Release|

Årsstämma Biovica International 2016

Biovica International höll årsstämma den 4:e oktober. VD Anders Rylander föredrog året i korthet och redogjorde för verksamhetsårets milstolpar. Biovica erhöll beslut om forskningsstöd från Horizon 2020 på 6,5 MSEK, med en första utbetalning på 2,2 MSEK. Biovica tog sin enskilt största order på 2,3 MSEK från en av världens ledande CRO:er, som förvärvat en [...]

2017-01-03T10:42:35+00:00 October 11th, 2016 15:41|Press Release|

Meet Biovica at the World CDx Summit in Boston

Biovica will attend the 7th World Companion Diagnostic in Boston, October 18-21. The focus of the meeting is aligned with Biovicas strategy to rapidly progress exploratory biomarkers to registration, align clinical co-development and ensure reimbursement and market access success for precision therapies and assays. “At the World CDx meeting we look forward to meet partners [...]

2017-01-03T10:42:56+00:00 September 28th, 2016 09:31|News|